Italy's Newron Pharmaceuticals has disclosed that the FDA kept U.S. enrollment in a Phase 3 trial of its schizophrenia drug evenamide on hold, citing five deaths across all the drug's clinical studies ...

Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us ...

Zealand Pharma shares fell about 4% in Thursday trading after new Phase 2 results for its Roche-partnered obesity drug petrelintide showed encouraging weight loss but a modest improvement in blood ...

Paris-based Rivercell has raised $25 million (about €22 million) in seed funding to generate experimental data and build AI ...

Swiss biotech ADC Therapeutics has secured an $86.6 million (€77.5 million) financing agreement alongside debt and royalty ...

Genmab and AbbVie's bispecific antibody epcoritamab, added to R-CHOP chemoimmunotherapy, cut the risk of progression or death by 51% in a Phase 3 trial in newly diagnosed diffuse large B-cell lymphoma ...

Roche has partnered with China’s Defand Therapeutics to discover molecular glue degraders for cancer and immune diseases, in a research and licensing agreement reportedly worth close to $1 billion ...

France’s WhiteLab Genomics has raised $26 million (€23 million) in Series B financing to expand experimental validation of ...

Dutch life sciences investor Forbion has raised €2.3 billion across two new funds to finance about 30 biotech companies, ...

Australian biopharma company CSL has entered an exclusive global partnership with Basel-based Alentis Therapeutics to ...

Oxford-based Sensible Biotechnologies has secured a $47 million (€42 million) financing package to scale a platform that ...

Genmab’s rinatabart sesutecan (Rina-S) delivered durable responses in a Phase 2 trial in platinum-resistant ovarian cancer, providing encouraging validation for the centerpiece of its $1.8 billion ...